Zhejiang Medicine Co (SHSE:600216) COGS-to-Revenue : 0.57 (As of Mar. 2025)

View and export this data going back to 1999. Start your Free Trial

What is Zhejiang Medicine Co COGS-to-Revenue?

Zhejiang Medicine Co's Cost of Goods Sold for the three months ended in Mar. 2025 was ¥1,277 Mil. Its Revenue for the three months ended in Mar. 2025 was ¥2,255 Mil.

Zhejiang Medicine Co's COGS to Revenue for the three months ended in Mar. 2025 was 0.57.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Zhejiang Medicine Co's Gross Margin % for the three months ended in Mar. 2025 was 43.40%.

Zhejiang Medicine Co COGS-to-Revenue Historical Data

The historical data trend for Zhejiang Medicine Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Medicine Co COGS-to-Revenue Chart

Zhejiang Medicine Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.58

0.59

0.66

0.68

0.58

Zhejiang Medicine Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															0.67	0.62	0.52	0.51	0.57

Zhejiang Medicine Co COGS-to-Revenue Calculation

Zhejiang Medicine Co's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	5406.541	/	9375.217
	=	0.58

Zhejiang Medicine Co's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1276.624	/	2255.389
	=	0.57

Zhejiang Medicine Co (SHSE:600216) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Zhejiang Medicine Co's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	1276.624 / 2255.389
	=	43.40 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Zhejiang Medicine Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Zhejiang Medicine Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhejiang Medicine Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Medicine Co Ltd (SHSE:600216) » Definitions » COGS-to-Revenue

Traded in Other Exchanges

N/A

Address

Comprehensive Building, No. 398 Mahuan Road, 3rd Floor, Building A, Binhai New City, Shaoxing, CHN, 312366

Website

http://www.china-zmc.com

Zhejiang Medicine Co Ltd is a china-based pharmaceutical company. The company manufactures fat-soluble vitamins, vitamins, quinolones, and antibiotic-resistant antibiotics, vitamin E, natural vitamin E, beta-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin.

Executives

Zhu Jin Lin	senior management
Chu Zhen Hua	Director
Liang Bi Rong	Director
Yu Yu Qing	Director
Ping Jian Hong	senior management
An Yong Bin	senior management
Wang Xiao Ping	senior management
Liang Li Ping	senior management
Li Qi Rong	senior management
Zhu Shao Ming	Supervisors
Wang Hong Wei	senior management
Zhang Ding Feng	senior management
Ma Wen Xin	Director
Zhao Jun Xing	senior management
Lv Yong Hui	Director

Zhejiang Medicine Co Headlines

No Headlines